Pegorgotein (formerly known as PEG-SOD) was developed by Enzon pharmaceutical as a scavenger of oxygen-derived free radicals. This drug under the trade name DISMUTEC participated in phase III clinical trial in patients with a severe closed head injury. It was found that the drug failed to show a statistically significant difference between the treatment group and the control group. In spite of DISMUTEC exhibited longer circulating half-life and reduced immunogenicity; however, the drug showed insufficient therapeutic effect for this indication. In addition, pegorgotein was studied for patients with reperfusion injury and stroke. However, these studies were also discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/β-catenin signaling pathway. | 2012-07-01 |
|
| Angiotensin II induces oxidative stress in prostate cancer. | 2008-02 |
|
| Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. | 2003-06 |
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 09:24:19 GMT 2025
by
admin
on
Wed Apr 02 09:24:19 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
3BNM95AKTO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7336
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
3BNM95AKTO
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
C166666
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
m10401
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
155773-57-2
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
3086673
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
DTXSID80165964
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
FF-31
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
300000034289
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108560
Created by
admin on Wed Apr 02 09:24:19 GMT 2025 , Edited by admin on Wed Apr 02 09:24:19 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_55 | 1_144 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUION | [1_6] | C | S-PALMITOYL CYSTEINE | 08WQ73S7SV | ||
| METAL BINDING | [1_44] [1_46] [1_61] [1_118] | CUPRIC CATION | 8CBV67279L | |||
| AMINO ACID SUBSTITUION | [1_1] | A | N-ACETYLALANINE | 26C4VY6Z0M | ||
| METAL BINDING | [1_61] [1_69] [1_78] [1_81] | ZINC CATION | 13S1S8SF37 | |||
| AMINO ACID SUBSTITUION | K |
Amount:
|
SUCCINYL MPEG 5000 LYSINE | 0W0Q819Z58 | ||
| AMINO ACID SUBSTITUION | [1_3] [1_9] | K | N6-SUCCINYLLYSINE | 3LH35AJA5L |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:ESTIMATE | CHEMICAL |
|